Flexion Therapeutics Sees Unusually Large Options Volume (FLXN)

Flexion Therapeutics Inc (NASDAQ:FLXN) was the recipient of unusually large options trading on Wednesday. Stock investors acquired 1,991 call options on the company. This represents an increase of 1,911% compared to the typical volume of 99 call options.

In related news, insider Michael D. Clayman acquired 4,046 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The stock was purchased at an average cost of $12.36 per share, for a total transaction of $50,008.56. Following the purchase, the insider now directly owns 70,856 shares of the company’s stock, valued at approximately $875,780.16. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 14.59% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. grew its holdings in Flexion Therapeutics by 6.6% in the third quarter. JPMorgan Chase & Co. now owns 152,355 shares of the specialty pharmaceutical company’s stock valued at $2,851,000 after purchasing an additional 9,460 shares during the period. Vanguard Group Inc grew its holdings in Flexion Therapeutics by 1.1% in the third quarter. Vanguard Group Inc now owns 1,619,112 shares of the specialty pharmaceutical company’s stock valued at $30,294,000 after purchasing an additional 18,323 shares during the period. Capital International Investors acquired a new stake in Flexion Therapeutics in the third quarter valued at approximately $12,162,000. Virtu Financial LLC purchased a new position in shares of Flexion Therapeutics in the fourth quarter valued at approximately $240,000. Finally, Next Capital Management LLC purchased a new position in shares of Flexion Therapeutics in the fourth quarter valued at approximately $84,000. 94.40% of the stock is currently owned by institutional investors.

A number of equities research analysts have commented on the company. Raymond James reiterated a “buy” rating on shares of Flexion Therapeutics in a research note on Thursday, March 28th. BidaskClub raised Flexion Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, March 29th. ValuEngine lowered Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. Laidlaw set a $18.00 price objective on Flexion Therapeutics and gave the company a “buy” rating in a report on Thursday, April 11th. Finally, Zacks Investment Research lowered Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, February 20th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. Flexion Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $22.64.

Flexion Therapeutics stock traded up $0.10 during midday trading on Friday, hitting $10.77. 467,239 shares of the company were exchanged, compared to its average volume of 649,260. The company has a quick ratio of 7.58, a current ratio of 7.78 and a debt-to-equity ratio of 1.35. Flexion Therapeutics has a fifty-two week low of $9.90 and a fifty-two week high of $29.10. The firm has a market cap of $409.19 million, a price-to-earnings ratio of -2.40 and a beta of 1.57.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings data on Thursday, February 28th. The specialty pharmaceutical company reported ($1.07) EPS for the quarter, beating the consensus estimate of ($1.24) by $0.17. Flexion Therapeutics had a negative return on equity of 102.16% and a negative net margin of 753.24%. The company had revenue of $9.54 million for the quarter, compared to analyst estimates of $9.40 million. Equities analysts expect that Flexion Therapeutics will post -4.12 EPS for the current year.

WARNING: “Flexion Therapeutics Sees Unusually Large Options Volume (FLXN)” was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/05/04/traders-purchase-large-volume-of-call-options-on-flexion-therapeutics-flxn.html.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Featured Story: How Investors Can Profit from Options Trading

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.